COMMUNIQUÉS West-GlobeNewswire

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical [...]
Precipio Announces Q1 2026 Financial Results
14/05/2026
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc [...]
HEALIOS K.K. to Present at Jefferies Global Healthcare Conference
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in New York City as [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. ( [...]
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
14/05/2026
Includes Full Exercise of $15.0 million Over-Allotment Option MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for [...]
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
14/05/2026
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion [...]
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
14/05/2026
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support [...]
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center [...]
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
First Tracks launched April 20 th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, [...]
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
14/05/2026
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and [...]
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
14/05/2026
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral [...]
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
14/05/2026
Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new [...]
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ [...]
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
14/05/2026
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled [...]
Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
14/05/2026
-- Zola ® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia’s history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of [...]
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
14/05/2026
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million Q1 2026 fully [...]
SRx Health Solutions Announces Fiscal Second Quarter 2026 Results for Quarter Ended March 31, 2026
14/05/2026
Q2 FY26 Marks Operational Inflection Point with Sequential 23% Revenue Growth and 44% Adjusted EBITDA Loss 1 Improvement Strengthened Liquidity and Working Capital Position with Cash of $20.5 million as of Quarter End [...]

Pages